Dr. John Kang reviews new lung cancer studies from the ASTRO conference
Fred Hutch Cancer Center – Proton Therapy lung cancer specialist John Kang, MD, PhD, recently attended the American Society for Radiation Oncology (ASTRO) conference in Seattle. Scientific conferences like ASTRO help keep Kang and other Fred Hutch clinicians up to date on the latest developments in the field.
“My students presented research that examined outcomes of protons versus photons in lung cancer patients treated at our center between 2018 and 2024,” he said. “We found that both modalities had similar toxicities, but protons allowed us to treat tumors that were 25-30% larger in volume with similar outcomes.”
Scientists expect more toxicities and side effects with bulkier tumors, including pneumonitis and esophagitis as well as future cardiac events. Larger tumors are also generally considered more advanced and deadlier. Because more radiation is needed to target a larger tumor, there is greater potential for radiation to impact healthy tissue.
The nature of proton therapy, however, allows more precise targeting than X-ray radiation. As a result, it spares more of the surrounding healthy tissue as providers increase the dose to more effectively destroy cancer cells.
These findings, Kang said, are good news for patients with larger tumors, as are two other studies presented at ASTRO. One showed that by sparing at least one side of the esophagus from radiation in patients undergoing lung cancer treatment, physicians were able to significantly reduce side effects. The study looked at photon treatment, but Kang said it had positive implications for proton therapy as well.
The other study showed seven- to ten-year outcomes after radiation in healthy, early-stage lung cancer patients were similar to those of surgery-only patients.
“This study is important because there’s a misconception that radiation is inferior to surgery,” Kang said.
Radiation is frequently reserved for more advanced cases and much sicker patients. But this study showed that the seven-year survival rate for radiation patients was 81% compared to 70% for surgery in early-stage cancer.
“The margins of error of the two modalities overlap, meaning that outcomes are considered similar, not better,” he said.
Fred Hutch is the only facility in Washington and surrounding states offering proton therapy as a treatment option, which gives patients and providers more flexibility when considering treatments.